EUCTR2008-003698-42-FR进行中（未招募）不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AF
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 14,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of informed consent prior to any study specific procedures
- •2.Female or male aged =18 years
- •3.Rhythm verification
- •Patient with paroxysmal AF: Clinically significant paroxysmal AF with at least one documented episode of AF within 12 months. The AF can be documented by 12 lead electrocardiogram (ECG), Holter, event recorder or telemetry, but not by pacemaker
- •Patient with permanent or persistent AF: AF documented on two occasions >7 days apart within 12 months. The AF can be documented by 12 lead ECG, Holter, event recorder or telemetry, but not by pacemaker
- •4.Stroke risk classification:
- •At least one of the following risk factors:
- •·Prior ischaemic stroke, TIA 6 and/or systemic embolism
- •·Patient aged =75 years
- •If neither of the risk factors above, at least two of the following risk factors are required:
- •·Hypertension
- •·Symptomatic CHF and/or left ventricular ejection fraction (LVEF) <=35%
- •·Diabetes mellitus
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Women of childbearing potential without a reliable form of contraception, as judged by the Investigator, before and during participation in the study
- •2.Lactation
- •3.AF secondary to a current reversible disorder, (eg, hyperthyroidism, isolated postoperative AF, drugs and pulmonary embolism)
- •4.Allergic and/or intolerant to VKA
- •5.Valvular heart disease if
- •·Any mitral valve prosthesis, or
- •·Mechanical valve prosthesis, or
- •·Mitral stenosis, or
- •·Any other valvular heart disease considered to significantly increase the risk of thromboembolic events or considered hemodynamically significant or expected to require surgical intervention during the course of the study
- •6.Active infective endocarditis
- •7.Any condition other than AF requiring chronic anticoagulation treatment
- •8.Myocardial Infarction (MI), heart surgery (eg, coronary artery bypass grafting, CABG) and/or percutaneous coronary intervention (PCI) within the 3 months prior to enrolment. Any prior PCI requiring clopidogrel treatment at the time of enrolment
- •9.Stroke, TIA and/or systemic embolism within the previous 14 days prior to randomisation
- •10.Known haemorrhagic disorders and/or conditions associated with increased risk of major bleeding
- •11.Severe renal impairment (calculated creatinine clearance (CrCL) <30 mL/min)
- •12.Known hepatic disease and/or ALT >3xULN and/or bilirubin >2xULN
- •13.Uncontrolled hypertension, systolic blood pressure =180 mmHg
- •14.Anemia (Hb<100g/L = 6.2 mmol/L) and/or platelet count <100x10 9/L
- •15.Planned pulmonary vein ablation procedure, PCI or major surgery. Planned cardioversion (direct current (DC) or pharmacological) within 1 month of randomisation.
- •16.Other serious disease that gives an estimated survival less than 12 months, any condition making a patient too frail to participate in the study, and/or inability to complete the study according to the protocol. Severe neurological deficit or disability that would interfere with the detection and/or assessment of a new cerebrovascular event
- •17.Known drug addiction and/or alcohol abuse
- •18.Previous enrolment or randomisation of treatment in the present study and/or participation in a previous study with AZD0837
- •19.Participation in another clinical study with IP and/or intervention during the last 3 months
- •20.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
研究者
相似试验
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFthe prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-003698-42-DKAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-SEAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-BGAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFthe prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-003698-42-DEAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-HUAstraZeneca AB14,600